Skip to main navigation Skip to search Skip to main content

用于治疗骨髓纤维化的Janus活化激酶2/Fms样酪氨酸激酶3抑制剂新药帕克替尼

Translated title of the contribution: Pacritinib:a new Janus activated kinase 2/Fms-like tyrosine kinase 3 inhibitor for the treatment of myelofibrosis
  • 王 咏懿
  • , 黄 璐
  • , 纪 雪梅*
  • *Corresponding author for this work
  • 中国药科大学药学院
  • 中国药科大学生命科学与技术学院

Research output: Contribution to journal › Review › peer-review

Abstract

Myelofibrosis(MF)is a myeloproliferative neoplasms(MPN),usually accomplies with thrombocytopenia,severely impacts the life quality of patients and presents a risk for leukemic transformation.Pacritinib is a kind of Janus activated kinase 2(JAK2)and Fms-like tyrosine kinase 3(FLT3)inhibitor.U.S.FDA has granted accelerated approval for pacritinib capsules(Vonjo),on Feb 28,2022,in the treatment of adult patients with the platelet(blood clotting cells)levels below 50000·μL^(-1)who have a rare form of bone marrow disorder known as intermediate or high-risk primary and secondary myelofibrosis.The oral dose of 200 mg twice daily showed good clinical efficacy and manageable safety.In this paper,the mechanism of action,pharmacodynamics,pharmacokinetics,safety,and clinical efficacy of daridorexant are reviewed.
Translated title of the contributionPacritinib:a new Janus activated kinase 2/Fms-like tyrosine kinase 3 inhibitor for the treatment of myelofibrosis
Original languageChinese
Pages (from-to)994-999
Number of pages6
JournalChinese Journal of New Drugs
Volume32
Issue number10
StatePublished - 1 May 2023

Indexed by

  • Scopus
  • CSCD

Fingerprint

Dive into the research topics of 'Pacritinib:a new Janus activated kinase 2/Fms-like tyrosine kinase 3 inhibitor for the treatment of myelofibrosis'. Together they form a unique fingerprint.

Cite this